108 completed, 40 unknown, 15 withdrawn, 14 terminated. 194 Phase 1, 99 Phase 2.
Follow Ischemia: new trials by email Literature Review of Ischemia trials Research Report on Ischemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FGF-1 for Intramuscular Injection for the Treatment of Peripheral Arterial Disease FGF-1, Placebo - Peripheral Arterial Disease, Stenosis | Phase 1 / Phase 2 | Not yet recruiting | Venturis Therapeutics, Inc. | 24 | 2028-10-15 | 2026-08-19 |
| The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cerebral Infarction Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#), Aspirin Tablet - Cerebral Infarction | Phase 1 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| Human Umbilical Cord Mesenchymal Stem Cell Therapy (19#iSCLife®-CI) for Cerebral Infarction Patients in Convalescent Period. Allogeneic umbilical cord mesenchymal stem cell, Aspirin Enteric-coated Tablets & Atorvastatin Calcium - Cerebral Infarction | Phase 1 / Phase 2 | Suspended | Sclnow Biotechnology Co., Ltd. | 40 | 2026-12-31 | 2026-04-23 |
| Safely Quenching Complement in Stroke Survivors Pegcetacoplan Injection [Empaveli] - Acute Ischemic Stroke, Cerebral Infarction | Phase 1 | Not yet recruiting | Columbia University | 20 | 2026-10-01 | 2026-04-29 |
| A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) STX-1150 - Elevated LDL-C and High Cholesterol | Phase 1 | Recruiting | Monash University | 64 | 2026-06-30 | 2026-09-21 |
| Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability Psilocybin (Usona Institute) - Stroke, Chronic Stroke | Phase 1 | Recruiting | Johns Hopkins University | 20 | 2026-02-09 | 2026-02-13 |
| Safety and Efficacy of FAP iCDC in Acute Myocardial Infarction With Cardiogenic Shock FAP allogeneic immunosuppressive CAR-DC - Cardiogenic Shock, Cardiogenic Shock Post Myocardial Infarction | Phase 1 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 18 | 2026-01-20 | 2026-02-02 |
| Safety and Efficacy of Epicardial Implantation of Collagen Membranes With Allogeneic Adipose Derived Stem Cells VB-C01 cellularised patch - CABG-patients, Heart Failure | Phase 1 | Not yet recruiting | Viscofan | 10 | 2025-09-01 | 2025-05-04 |
| Accelerated rTMS vs. Sham for Stroke Apathy MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Active), MagVenture MagPro Transcranial Magnetic Stimulation (TMS) System (Sham), Brainsight Neuronavigation System - Apathy, Stroke | Phase 1 / Phase 2 | Recruiting | Medical University of South Carolina | 40 | 2025-08-08 | 2026-07-08 |
| A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care. AK1967 (Invobenitug also known as Procizumab), Placebo - Shock, Cardiogenic | Phase 1 / Phase 2 | Recruiting | 4TEEN4 Pharmaceuticals GmbH | 90 | 2025-07-13 | 2026-09-14 |
| The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial. Autologous hMSCs, Autologous Human C-Kit CSCs II, Placebo - Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction | Phase 1 / Phase 2 | Withdrawn | Joshua M Hare | 2025-03-01 | 2020-10-22 | |
| Pilot Study of IC14 (Atibuclimab), an Anti-CD14 Monoclonal Antibody, to Treat STEMI Atibuclimab (IC14), 20 mg/kg intravenously, once, Placebo, 150 mL intravenously, once - STEMI, STEMI (ST Elevation MI) | Phase 1 / Phase 2 | Active not recruiting | Implicit Bioscience | 10 | 2025-02-06 | 2026-03-27 |
| A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction SGC001, Placebo - Anterior Myocardial Infarction | Phase 1 | Completed | Beijing Sungen Biomedical Technology Co., Ltd | 38 | 2025-01-20 | 2026-01-12 |
| Tolerance Study of Allogeneic of Adipose Tissue Derived Mesenchymal Stroma/Stem Cells (AdMSC) Transplantation in Patients With Critical Limb Ischemia. Adipose tissue derived mesenchymal Stroma/stem Cells transplantation - Critical Limb Ischemia | Phase 1 | Not yet recruiting | University Hospital, Toulouse | 10 | 2025-01-01 | 2025-01-28 |
| A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects SGC001, Placebo - Anterior Myocardial Infarction | Phase 1 | Completed | Beijing Sungen Biomedical Technology Co., Ltd | 49 | 2024-08-20 | 2025-11-25 |
| A Safety and Efficacy Trial of Istaroxime for Cardiogenic Shock Stage C Istaroxime, Placebo - Cardiogenic Shock | Phase 1 / Phase 2 | Active not recruiting | Windtree Therapeutics | 20 | 2024-06-01 | 2025-08-20 |
| Safety and Preliminary Efficacy of Allogeneic Endothelial Progenitor Cells (EPCs) in Patients With Critical Limb Ischemia EPCs, Clinical standard treatment (CST) - Critical Limb Ischemia | Phase 1 | Unknown | Allife Medical Science and Technology Co., Ltd. | 27 | 2024-04-01 | 2024-04-11 |
| Oral Nicorandil for Prevention of No Reflow Phenomenon in Anterior STEMI Patients Undergoing PPCI Nicorandil 20mg - No Reflow Phenomenon, Anterior STEMI | Phase 1 / Phase 2 | Completed | Ain Shams University | 300 | 2024-03-10 | 2025-08-24 |
| Individualized or Conventional Transfusion Strategies During Peripheral VA-ECMO Packed Red Blood Cells (PRBCs) - Cardiogenic Shock, Extracorporeal Membrane Oxygenation | Phase 1 | Recruiting | University Hospital, Lille | 236 | 2023-09-18 | 2026-09-17 |
| Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets - Obstructive Pulmonary Function, Restrictive Pulmonary Function | Phase 1 | Terminated | Vectura, Inc. | 4 | 2023-03-11 | 2024-03-22 |
Showing 20 of 194. Sign in to see all of them.
Myocardial Infarction (71) · Chronic Limb-Threatening Ischemia (49) · Stroke (27) · Peripheral Vascular Diseases (21) · Peripheral Arterial Disease (20) · Coronary Artery Disease (15) · Heart Failure (15) · Ischemic Stroke (13) · ST Elevation Myocardial Infarction (13) · Cerebral Infarction (10) · Cardiovascular Diseases (9) · Diabetic Foot (9) · Infarction, Middle Cerebral Artery (9) · Heart Diseases (8)
Pathological Conditions, Signs and Symptoms (194) · Pathologic Processes (192) · Cardiovascular Diseases (177) · Vascular Diseases (177) · Necrosis (110) · Infarction (100) · Heart Diseases (85) · Myocardial Ischemia (82) · Arteriosclerosis (68) · Arterial Occlusive Diseases (65) · Atherosclerosis (52) · Chronic Disease (50) · Disease Attributes (50) · Nervous System Diseases (38)
Sodium Chloride (5) · Saline Solution (4) · Aspirin (3) · Lipectomy (3) · Standard of Care (3) · Atorvastatin (2) · Cell- and Tissue-Based Therapy (2) · Fish Oils (2) · Omacor (2) · Plasmalyte A (2) · Ranibizumab (2) · 3-(2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl)phenol (1) · Adenosine (1) · Adenosine Monophosphate (1) · Alprazolam (1)
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (3) · Cedars-Sinai Medical Center (3) · Jie Shen (3) · Losordo, Douglas, M.D. (3) · Mayo Clinic (3) · Xijing Hospital (3) · Ageless Regenerative Institute (2) · Beijing Sungen Biomedical Technology Co., Ltd (2) · Bioheart, Inc. (2) · China Medical University Hospital (2) · Emory University (2) · Helixmith Co., Ltd. (2) · Imperial College London (2) · Odense University Hospital (2) · Pluristem Ltd. (2)
United States (78) · China (20) · Germany (10) · Spain (9) · Netherlands (7) · France (6) · India (6) · Israel (6) · Canada (5) · Denmark (5) · Taiwan (5) · Brazil (4) · South Korea (4) · Switzerland (4) · United Kingdom (4)
Jie Shen (3) · Michael P Murphy, MD (3) · Antonio Abbate, MD, PhD (2) · Eduardo Marban, MD, PhD (2) · Nicolas Chronos, MD (2) · Takayuki Asahara, M.D. (2) · Timothy Henry, MD (2) · Warren Sherman, MD (2) · Adelino Leite-Moreira, PhD (1) · Alexander Reyzelman, MD (1) · Alexandre Mebazaa, Professor (1) · Alisha Oropallo, MD (1) · Amish N Raval, MD (1) · Ana Paula CP Carlotti, 1 (1)
PMID 35802393, PMID 22163120, PMID 25102193, PMID 15246726, PMID 16282547, PMID 16336965, PMID 18468545, PMID 19301723, PMID 19570514, PMID 19679246, PMID 19711453, PMID 19958962, PMID 19996767, PMID 20078390, PMID 20236457, PMID 20705929, PMID 20966420, PMID 21325598, PMID 21330601, PMID 21422390, PMID 21454794, PMID 21492763, PMID 21502572, PMID 21594960, PMID 21658561, PMID 21717276, PMID 22052917, PMID 22088800, PMID 22198979, PMID 22264202, PMID 22336189, PMID 22764211, PMID 22877866, PMID 22951358, PMID 22965994, PMID 22971949, PMID 23192920, PMID 23197640, PMID 23370205, PMID 23594433, PMID 23633132, PMID 23758736, PMID 23778184, PMID 23979567, PMID 24001533, PMID 24036024, PMID 24218170, PMID 24300013, PMID 24610327, PMID 24691607
2008 (1), 2014 (1), 2018 (1), 2023 (1), P50NS044148 (1), R01HD065438 (1), R01HL103927 (1), RC3HL103356-01 (1), U54HL081028 (1)